Stonehaven Incubate and Nuritas have announced a new collaboration which will see them join forces as part of a newly created joint venture. This world leading partnership will use cutting-edge AI technology to discover and develop advanced animal health solutions, with an initial focus on exploring feed ingredients.
Stonehaven Incubate is a dedicated, animal health group committed to creating new companies from disruptive human technology. Nuritas, which combines artificial intelligence and genomics to discover and unlock natural Bioactive Peptides with extraordinary health benefits, is exactly the type of company with which it looks to forge partnerships.
Dr Mark Heffernan CEO of Stonehaven Incubate, said: “We see working with Nuritas on the use of its artificial intelligence platform to identify bioactive peptides as novel animal health solutions. The initial phase of our work together will include establishing a new company focused on this platform for animal health and conducting a series of evaluation trials.”
Emmet Browne, CEO of Nuritas, said: “We have long recognised the considerable opportunity for Nuritas within animal health. This partnership will deliver a unique and winning edge in this space by pairing Stonehaven Incubate’s deep industry specific understanding and experience with Nuritas’ ground-breaking technology.” Browne added: “The formation of the new company will enable us to focus on adding significant value to existing Nuritas discoveries in the field of animal health in addition to partnering externally on specific ground-breaking new projects. We have already experienced significant success with our unique discovery platform in the human world and now we are delighted to complement this with truly game-changing collaborations in the animal world.”
ends
Notes to editor:
Stonehaven Incubate
Swiss based Stonehaven Incubate was formed in February 2018 and is a dedicated, animal health group committed to creating new companies de novo from disruptive human technology. Stonehaven Incubate works with innovators and builds strategies for new, stand-alone animal health companies. It finds experienced management teams and sources the required capital, leaving no stone unturned in its quest to bring human innovations to animal health.
Its parent company, Stonehaven Holding was formed in 2017 by George Gunn and Matthias Hofer. www.stonehaven-incubate.com
For more information contact Mike Keeler or Alistair Moses at Garnett Keeler PR on +44 (0)20 8647 4467 or mike.keeler@garnettkeeler.com / alistair.moses@garnettkeeler.com
Nuritas
Founded in 2014 by mathematician and bioinformatician Dr Nora Khaldi, Nuritas is the first company in the world to demonstrate that AI can accelerate the discovery of a healthcare product from concept to market in less than 3 years. Nuritas is a discovery platform for active peptides that can prevent or treat disease with industry leading speed and accuracy. It is successfully doing so in current collaborations with a number of industry leading multinationals. The multi-award-winning company is changing the landscape of drug discovery by identifying novel peptides using a proprietary artificial intelligence (AI) platform, with in-silico predictions validated by their in-house laboratory and multidisciplinary team of scientists.
For more information contact Thérèse Holton or Audrey Wall at Nuritas on +353 1 430 1290 or info@nuritas.com
STO/046/19
